Wall Street analysts forecast that Danaher (DHR) will report quarterly earnings of $1.89 per share in its upcoming release, pointing to a year-over-year decline of 34.2%. It is anticipated that revenues will amount to $5.99 billion, exhibiting a decline of 28.4% compared to the year-ago quarter.The current level reflects an upward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their ini ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Danaher (DHR) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 30, 2024, might help the stock move higher if these key numbers are better than expecta ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Danaher (DHR) , which belongs to the Zacks Diversified Operations industry, could be a great candidate to consider.When looking at the last two reports, this industrial and medical device maker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 6.44%, on average, in the last two quarters.For the last repo ...

In the latest market close, Danaher (DHR) reached $229.64, with a -0.53% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.57%. Elsewhere, the Dow gained 0.46%, while the tech-heavy Nasdaq added 0.75%.Coming into today, shares of the industrial and medical device maker had gained 5.06% in the past month. In that same time, the Conglomerates sector gained 0.1%, while the S&P 500 gained 3.4%.The investment community will be paying close attention to the e ...

Key PointsDanaher raised its guidance expectation and sent shares soaring. Analysts underestimate the company's performance, setting it up to rebound in 2024. The question for investors is whether this stock will rally higher in the year's first half or pull back to firmer support before moving higher later in the year. 5 stocks we like better than DanaherDanaher Corporation NYSE: DHR shares went into a tailspin when the Abcam deal came into question, but the dip turned out to be a buying opportunity in thi ...

Danaher Corporation (NYSE:DHR) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 2:15 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Good afternoon, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team here at JP Morgan. Thank you for coming to the Danaher presentation. This will be a 40-minute session as we typically do roughly 20 minutes of a presentation foll ...

New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses Innovative model aims to dramatically reduce preclinical and clinical development time and expense for investigational rare disease therapies that currently struggle to attract funding Nobel laureate Doudna and team to partner with Danaher to oversee center's translational and clinical researc ...

WASHINGTON, Jan. 8, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2023 performance in a presentation at the J.P. Morgan Healthcare Conference at 2:15 p.m. ET. For the fourth quarter 2023, estimated revenues are anticipated to decrease in the low-double digit percent range year-over-year. Estimated non-GAAP core revenue for the fourth quarter of 2023 is expe ...

The latest trading session saw Danaher (DHR) ending at $230.81, denoting a -1.7% adjustment from its last day's close. This change lagged the S&P 500's 0.8% loss on the day. Meanwhile, the Dow experienced a drop of 0.76%, and the technology-dominated Nasdaq saw a decrease of 1.18%.Shares of the industrial and medical device maker have appreciated by 7% over the course of the past month, outperforming the Conglomerates sector's gain of 5.58% and the S&P 500's gain of 3.4%.The upcoming earnings release of Dan ...

WASHINGTON, Jan. 2, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024 at 2:15 p.m. ET. The event will be simultaneously webcast on www.danaher.com. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our ...